Acalabrutinib – July 2023

Acalabrutinib: Tablet 100 mg; Calquence®

Brand names:
- Calquence®
Pharmaceutical Company:
- AstraZeneca Pty Ltd
Condition/Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Meeting Date: July 2023
Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 910KB)
Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 503KB)

Last updated

5 July 2023